Introduction
Access to medical cannabis in South Africa is often misunderstood. While public discourse has largely focused on the decriminalisation of private use, the legal framework governing medical cannabis remains structured, regulated, and rooted in healthcare protocols. At the centre of this framework is Section 21 of the Medicines and Related Substances Act, which provides a lawful pathway for patients to access cannabis-based medicines under medical supervision.
What is Section 21?
Section 21 is a provision within South African law that allows for the use of unregistered medicines under specific conditions. In the context of medical cannabis, this means that a doctor may prescribe a cannabis-based product for a patient, even if that product is not formally registered as a medicine in South Africa — provided that regulatory approval is obtained. This approval is granted by SAHPRA on a patient-specific basis.
Why is Section 21 Necessary?
Medical cannabis is classified as a scheduled substance, which means its use must be carefully controlled. Unlike over-the-counter products, cannabis-based medicines require clinical oversight, must be prescribed by a registered medical practitioner, and must be dispensed through authorised healthcare channels.
The Step-by-Step Process
Accessing medical cannabis through Section 21 follows a structured pathway:
- Consultation with a Medical Practitioner: A registered doctor evaluates the patient and determines whether cannabis-based treatment may be appropriate.
- Section 21 Application: If the doctor believes treatment is warranted, an application is submitted to SAHPRA for approval.
- SAHPRA Review and Approval: SAHPRA reviews the application and, if satisfied, issues an approval letter for that specific patient.
- Product Allocation: Once approval is granted, the prescribed product is sourced through a regulated supply chain.
- Dispensing: The product is dispensed by a licensed pharmacist or authorised dispensing practitioner.
What This Means in Practice
The Section 21 pathway is not a general retail mechanism — it is a controlled healthcare process. This means products are prescribed, not freely sold, approval is required for each patient, and dispensing must occur through regulated channels.
The Role of Quality and Compliance
Cannabis-based medicines supplied through this pathway should be manufactured within controlled, pharmaceutical-aligned environments, supported by Certificates of Analysis (COAs), and traceable through the supply chain. This ensures that patients receive products that are consistent, safe, and fit for medical use.
Conclusion
Medical cannabis in South Africa is accessible — but it is accessible through a regulated healthcare pathway. Section 21 ensures that this access is patient-specific, doctor-led, quality-controlled, and legally compliant. As the market matures, these principles will remain central to the responsible development of the sector.